People line up at a COVID-19 testing clinic Wednesday, March 24, 2021 in Montreal. THE CANADIAN PRESS/Ryan Remiorz

People line up at a COVID-19 testing clinic Wednesday, March 24, 2021 in Montreal. THE CANADIAN PRESS/Ryan Remiorz

The need for speed: How Canada approved five vaccines for COVID-19 in under a year

A sixth vaccine from Novavax is still under review, with the results not expected until next month

In the last four years, Health Canada has approved more than 1,500 new or updated pharmaceuticals.

Ten of them are vaccines.

Five of those are for COVID-19.

Dr. Supriya Sharma, the chief medical adviser at Health Canada helping oversee the review process, has never seen anything like the speed with which the COVID-19 vaccines got approved.

“I mean, unprecedented is the one word that we’ve been overusing, but there’s nothing even close to comparable to this,” she said in an interview.

The five non-COVID vaccines approved, four for influenza and one for shingles, took an average of 397 days from the day the company applied for approval in Canada, until that approval was granted.

The average time for COVID-19 vaccines? 82 days.

That includes 61 days for Pfizer-BioNTech, 72 days for Moderna, 95 days for Johnson & Johnson, 148 days for Oxford-AstraZeneca and 34 days for Covishield, the AstraZeneca vaccine produced by the Serum Institute of India.

Covishield is a slight outlier because Health Canada mostly just needed to review the manufacturing process, as the vaccine is the same formula as the AstraZeneca doses made elsewhere. Sharma likens it to the same recipe made in a different kitchen, but the kitchen still needs to be up to snuff.

A sixth vaccine from Novavax is still under review, with the results from its big clinical trial not expected until next month. It has been under review by Health Canada for 58 days at this point.

The speed has raised fears among Canadians that everything moved too quickly. Many medical experts worry it is contributing to hesitancy to get the vaccines.

But Sharma says speed did not come at the expense of safety.

“That’s the only priority, the only thought, is what’s best for Canadians,” she said. “There’s no other motivation anywhere.”

Lack of research funds can slow down new drug development, but in this case, as lockdowns shuttered economies worldwide and death tolls mounted, countries poured billions of dollars into getting a vaccine to get us out of the pandemic.

Most of the successful vaccines for COVID-19 so far use existing vaccine technology that was adjusted for the SARS-CoV-2 virus that causes COVID-19.

They start with lab studies to check for safety on animals and see how the vaccine works in a lab setting on blood samples and on samples of the virus.

Then it is tested on a very small number of humans to look for any glaring safety concerns. Then they test it on a slightly larger number of people — usually fewer than 100 — to look for safety and the development of antibodies.

If that goes well, the trial is expanded to thousands of volunteers, some of whom get the vaccine and some of whom don’t. Then they wait to see how many in each group get infected.

Phase 3 trials usually take between one and four years. For the vaccines approved in Canada so far, phase three trials took about three months.

Sharma said the time a trial takes depends on finding enough patients to participate, and then having enough of their trial participants get sick to know how well the vaccine is or isn’t working.

Fortunately and unfortunately, COVID-19 was spreading so rampantly in so many places, getting enough people exposed did not take very long.

Canada has seen very few vaccines tested here so far, mainly because our infection rates weren’t high enough.

While the drug makers were busy getting the trials going, Health Canada was getting ready for their submissions. Sharma said discussions about COVID-19 vaccines began in earnest with international bodies in mid-January 2020, before Canada had even had a single confirmed case.

“I think we knew that … we had a virus that was going to be transmissible, that could be causing significant respiratory disease, and that there would be an interest in therapies and vaccines definitely, very early on,” said Sharma.

It was determined quickly that this virus was so new there was no existing vaccine that could be adjusted quickly, as had happened with the H1N1 pandemic in 2009.

By March, Health Canada had started putting teams in place to review new therapies and vaccines for COVID-19 as soon as they were ready.

Each team was made up of 12 to 15 people, with varying specialties. There was some overlap between the teams but not a lot because many vaccines were being reviewed at the same time.

The experts on the file included infectious disease specialists, pharmacologists, biostatisticians, and epidemiologists.

Separate from that were teams of people looking at manufacturing facilities. Approving a vaccine isn’t just about making sure the clinical data shows it to be safe and effective, but also about making sure the place it is to be made follows the required safety standards.

They needed an emergency order from Health Minister Patty Hajdu to do a rolling review. Normally drug makers can’t apply until they have every piece of data ready but with a rolling review Health Canada scientists can start reviewing the data as it becomes available.

Hajdu granted that on Sept. 16.

Then the vaccine submissions began pouring in — AstraZeneca applied Oct. 1, Pfizer Oct. 9, Moderna on Oct. 12, and J&J on Nov. 30. The Covishield application came Jan. 23 and Novavax submitted on Jan. 29.

Sharma says the teams were working 15 to 18 hours a day, seven days a week, reviewing data, asking the companies questions, requesting more information or new analyses.

Sometimes they were doing it in the middle of the night. Collaborations with international partners in very different time zones, meant 2 a.m. or 4 a.m. video conference calls were not unusual.

When Pfizer and Moderna were reviewed, it was entirely based on clinical trail and pre-market data because the vaccines hadn’t been approved anywhere else. Canada was the third in the world to authorize Pfizer on Dec. 14th, and second to approve Moderna Dec. 23.

By the time Health Canada authorized AstraZeneca — a review process complicated by some mistakes during the clinical trial in dosing and the number of seniors among its volunteer patients — it was also able to pull data from real-world use of the vaccine in the United Kingdom.

The regulatory work doesn’t end when the authorization is announced. The post-market surveillance data is still non-stop. The recent blood clot concern with the AstraZeneca vaccine took a lot of time, but just monitoring the data submitted by the vaccine makers on adverse events overall is still critical.

To date, the adverse event reports in Canada have not been different than what was seen in clinical trials.

Companies also adjust their submissions requiring further review. Pfizer has so far asked for two changes, one to the number of doses per vial and another for the temperature at which the vaccine has to be kept.

If anything changes on safety, or if the efficacy seen in a clinical trial doesn’t play out in the real world, Sharma says Canada will not hesitate to make adjustments. But those decisions will be made by Canadian experts, said Sharma, the same ones who have been on the files all along.

“It’s important that if anything comes up, we have people that have reviewed it, have gone through every piece of paper, the 2,000 hours, the hundreds of thousands of pages, and that if anything comes up, it’s like they’ve got a really strong science base, and they can put that stuff in context and we can make decisions really quickly.”

READ MORE: ‘Stronger’ measures needed across Canada to suppress COVID-19 resurgence: Tam

Mia Rabson, The Canadian Press


Like us on Facebook and follow us on Twitter.

Want to support local journalism during the pandemic? Make a donation here.

Coronavirusvaccines

Get local stories you won't find anywhere else right to your inbox.
Sign up here

Just Posted

As of Friday, Alberta has under 10,000 active COVID-19 cases. (Image courtesy CDC)
Alberta reports 2,271 new COVID-19 cases, Red Deer cases rise slightly

Across Alberta, there are 666 people in hospital with COVID-19, including 146 in the ICU

Alberta Health Services locked the Whistle Stop Cafe at Mirror on Wednesday morning after owner Christopher Scott refused to comply with health orders.
Photo by Paul Cowley/Advocate staff
AHS shuts down Whistle Stop Cafe for defying health orders

Health inspectors and RCMP locked doors early Wednesday

Premier Jason Kenney (File photo by THE CANADIAN PRESS)
A vial of Oxford-AstraZeneca COVID-19 vaccine is seen at a facility in Milton, Ont., on Wednesday, March 3, 2021. An Alberta woman in her 50s has died from a rare blood clot disorder after receiving the AstraZeneca vaccine. THE CANADIAN PRESS/Carlos Osorio - POOL
Alberta confirms blood clot disorder death linked to AstraZeneca vaccine

Both AstraZeneca and Johnson & Johnson vaccines have been linked to VITT in a very small number of cases

Premier Jason Kenney says with COVID-19 numbers still rising, the province’s health-care system will be tested in the coming weeks. (photography by Winston Pon/Office of the Premier)
‘Please stay home’: Kenney imposes new COVID-19 restrictions

New measures will be in place for at least three weeks

FILE - In this March 3, 2021, file photo, a vial of the Johnson & Johnson COVID-19 vaccine is displayed at South Shore University Hospital in Bay Shore, N.Y. (AP Photo/Mark Lennihan, File)
Johnson & Johnson COVID vaccine can be given to adults 30+ who can’t wait for mRNA: NACI

Panel says single shot vaccine can be especially useful for populations unable to return for second shot

B.C.’s provincial health officer, Dr. Bonnie Henry. THE CANADIAN PRESS/Jonathan Hayward
Dip in COVID-19 cases with 572 newly announced in B.C.

No new deaths have been reported but hospitalized patients are up to 481, with 161 being treated in intensive care

A dose of the Pfizer COVID-19 vaccination is prepared at a mobile clinic for members of First Nations and their partners, in Montreal, Friday, April 30, 2021. THE CANADIAN PRESS/Ryan Remiorz
Pfizer-BioNTech vaccine approved for kids 12 to 15 years old in Canada

The vaccine was previously authorized for anyone at least 16 years of age or older

Prime Minister Justin Trudeau listens to speakers appearing by video during a news conference in Ottawa on Tuesday May 4, 2021. THE CANADIAN PRESS/Adrian Wyld
Canada will align policy on ‘vaccine passports’ with international allies: Trudeau

Trudeau says Canadians could begin travelling outside the country again by summer

Ranging from 11 to 20 in age and representing seven provinces and one territory, the plaintiffs are appealing a Supreme Court judge’s decision to dismiss their lawsuit last fall. (David Suzuki Foundation)
15 youths not backing down in their fight to sue Ottawa over climate change inaction

The group has filed an appeal after their lawsuit was struck down by a Federal Court judge last fall

A 2021 census questionnaire. (Black Press Media file photo)
2021 census responses due May 11

By law, every household must complete a census questionnaire

Calgary Mayor Naheed Nenshi attends a senior’s home in Calgary on Tuesday, April 14, 2020, amid a worldwide COVID-19 pandemic. Nenshi says he’s frustrated to hear that tickets given to people for breaching COVID-19 public health orders are being thrown out in the courts.THE CANADIAN PRESS/Jeff McIntosh
‘Incredibly frustrating:’ Calgary mayor wants courts to uphold COVID-19 measures

Large groups without masks have been gathering in Calgary public spaces in protest of health measures

Jose Marchand prepares Pfizer COVID-19 vaccination doses at a mobile clinic for members of First Nations and their partners, in Montreal, Friday, April 30, 2021. The National Advisory Committee on Immunization is coming under fire after contradicting the advice Canadians have been receiving for weeks to take the first vaccine against COVID-19 that they’re offered. THE CANADIAN PRESS/Ryan Remiorz
NACI advice on ‘preferred vaccines’ for COVID-19 sparks confusion, anger

Panel said that people who can wait for an mRNA vaccine should do so

Michael Bonin, 20, from Alberta, was discovered deceased on Peers Creek Forest Service Road north of Hope on April 20, 2017. (Black Press Media)
1 of 3 accused in 2017 murder of Alberta man pleads guilty, sentenced to life in prison

Joshua Fleurant pleaded guilty in a Kelowna courtroom to the second-degree murder of Michael Bonin

Most Read